Novartis Cancer

03/14/2024

( ) are rare cancers that can develop in different organs and tissues, but the majority (more than 60%) originate in the digestive system. When they do, they are called gastroenteropancreatic neuroendocrine tumors, or GEP-NETs for short.

The journey to diagnosis is often long and takes a toll on patients’ overall wellbeing. On average, it can take over four years from first onset of symptoms to a final diagnosis, after an extensive medical journey, including many examinations and multiple specialists. Unfortunately, such delays mean that the majority of patients are initially diagnosed with advanced disease.

this
– we are presenting our discoveries on new ways to improve health outcomes for people with .

Learn more here: http://ms.spr.ly/6189cgpB3

03/13/2024

GEP-NETs are a diverse and heterogeneous group of tumors that originate in the gastrointestinal (GI) tract and pancreas. The symptoms are often vague and non-specific, and can be mistaken for other conditions, meaning diagnosis can take, on average, four years.

Most people diagnosed with this type of cancer express somatostatin receptors, located on the cancerous cell or tumor microenvironment. Radioligand therapy ( ) targets these receptors, to destroy or damage the cancer cell, with the goal of limiting impact on healthy tissues.

This learn more about our exploration of RLT as a potential therapy to transform the future of GEP-NETs cancer care.

Explore RLT here: http://ms.spr.ly/6182cgTLK

02/12/2024

The words we speak to our patients can have an impact that goes way beyond what they hear in the clinic room."

Hear Dr Shikha Jain, MD, FACP, Associate Professor of Medicine, University of Illinois, and expert on the My Cancer. My Words. Steering Committee, explain how the words that caregivers and health care professionals use can impact people living with cancer.

Find out more of Novartis' My Cancer. My Words. project at http://novartis.social/6188iFy2M

02/07/2024

Unsurprisingly, negative words are among the first that come to mind for most people diagnosed with cancer. But why does this matter?

Hear from Dr Simon De Deyne, Cognitive Scientist at the University of Melbourne, and one of the expert advisors researching the ways that people talk about cancer.

What words come to mind when you think about cancer?

Explore answers from 2,000 survey respondents across the UK and US, living with cancer or working in the cancer field: http://novartis.social/6187iFyS9

02/04/2024

Words matter. The language used when talking about cancer can have lasting effects on people living with cancer.

Listen to Claire Saxton, Executive Vice President for the Cancer Support Community, and member of the My Cancer. My Words. Steering Committee, on why it's important that people living with cancer, caregivers, and health care professionals openly talk about the preferences they have when it comes to the words used to describe cancer.

Find out more about our work regarding the way that language can impact people living with cancer at http://novartis.social/6180iFyby.

12/15/2023

Does the world need to change the way it talks about cancer?

The results are in from a new survey looking at how language could impact treatment decisions. Find out more here: https://bit.ly/4acGvg5

11/27/2023

Advanced or metastatic is complex. Being prepared for open conversations with your doctor can help navigate your journey to better care.

Ask questions and express concerns about your diagnosis, so together you can decide what works best for you. Information is key to get the right support–here are some helpful terms.

Learn more about prostate cancer https://go.novartis.social/3TaBEWL

11/19/2023

A diagnosis can be devastating and an emotional journey as symptoms often start to appear once the cancer is in its advanced stages, making it hardest to treat.

At Novartis, we are committed to supporting the lung cancer community to help those living with its realities feel hopeful in the advancements of science innovation for better care outcomes.

Learn more this : http://novartis.social/61809hcZu

11/15/2023

is a complex and emotional journey. At Novartis, we are committed to supporting education and awareness around prostate cancer to help those living with its realities feel empowered to take action for the care they want and deserve.

As you navigate living with advanced prostate cancer, know that you aren’t alone. Speak to your health care team to get the information to move forward.

Learn more about prostate cancer before your next doctor’s visit: http://novartis.social/61849hB1G

11/14/2023

The people behind our (RLTs) are leading the way in patient-centered manufacturing.

Every day, their deep connection to our patients and understanding of the potential impact of RLT on the lives of patients shines through in their work. http://novartis.social/61859htVJ

11/13/2023

About 10 million men are presently living with , and approximately 700,000 of them are living with metastatic disease.

Metastatic prostate cancer is when the cancer spreads to other parts of the body. Currently, patients diagnosed with metastatic prostate cancer have a 5-year survival rate of approximately 30%.

At Novartis, our mission is to push the boundaries of scientific advancements to help improve the current survival rates.

Staying proactive is key to managing disease. Speak with your doctor and have regular check-ups to keep on top of your prostate health.

11/10/2023

How can the leading cause of cancer deaths in men and women be called the “invisible cancer”?

Despite accounting for more than 2 million new diagnoses each year, the stigma and lack of information are important issues we need to address to improve treatment outcomes for those living with .

Learn more about lung cancer to help spread awareness of the condition and address barriers to overcome.

Lung cancer is a global disease.

We need more research, more screening, and more treatment options to improve outcomes and increase survival.